RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc.verified

RAPT

Price:

$9.19

Market Cap:

$319.79M

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development o...[Read more]

Industry

Biotechnology

IPO Date

2019-10-31

Stock Exchange

NASDAQ

Ticker

RAPT

The PE Ratio as of April 2024 (TTM) for RAPT Therapeutics, Inc. (RAPT) is -3.01

According to RAPT Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.01. This represents a change of -54.39% compared to the average of -6.60 of the last 4 quarters.

RAPT Therapeutics, Inc. (RAPT) Historical PE Ratio (quarterly & annually)

How has RAPT PE Ratio performed in the past?

The mean historical PE Ratio of RAPT Therapeutics, Inc. over the last ten years is -9.50. The current -3.01 PE Ratio has changed 3.07% with respect to the historical average. Over the past ten years (40 quarters), RAPT's PE Ratio was at its highest in in the September 2019 quarter at -0.26. The PE Ratio was at its lowest in in the December 2021 quarter at -15.06.

Quarterly (TTM)
Annual

Average

-9.50

Median

-8.16

Minimum

-14.75

Maximum

-6.23

RAPT Therapeutics, Inc. (RAPT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of RAPT Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 124.96%

Maximum Annual PE Ratio = -6.23

Minimum Annual Increase = -46.65%

Minimum Annual PE Ratio = -14.75

Quarterly (TTM)
Annual
YearPE RatioChange
2023-8.163.66%
2022-7.87-46.65%
2021-14.7563.67%
2020-9.01-35.72%
2019-14.02124.96%
2018-6.23-3.48%

RAPT Therapeutics, Inc. (RAPT) Average PE Ratio

How has RAPT PE Ratio performed in the past?

The current PE Ratio of RAPT Therapeutics, Inc. (RAPT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-10.26

5-year avg

-10.76

10-year avg

-9.50

RAPT Therapeutics, Inc. (RAPT) PE Ratio vs. Peers

How is RAPT’s PE Ratio compared to its peers?

RAPT Therapeutics, Inc.’s PE Ratio is less than Connect Biopharma Holdings Limited (-1.09), greater than Tyra Biosciences, Inc. (-9.59), less than Xilio Therapeutics, Inc. (-0.43), greater than Mineralys Therapeutics, Inc. (-7.25), less than Molecular Partners AG (-1.90), less than AN2 Therapeutics, Inc. (-1.27), greater than Pharvaris N.V. (-13.90), greater than PepGen Inc. (-4.04), greater than Monte Rosa Therapeutics, Inc. (-3.08), greater than Design Therapeutics, Inc. (-3.05), greater than Werewolf Therapeutics, Inc. (-4.67), less than Ikena Oncology, Inc. (-0.95), greater than Stoke Therapeutics, Inc. (-5.72), greater than Anebulo Pharmaceuticals, Inc. (-7.19), less than PMV Pharmaceuticals, Inc. (-1.38), greater than Eliem Therapeutics, Inc. (-3.51), less than HCW Biologics Inc. (-2.44), less than Relay Therapeutics, Inc. (-2.57), greater than Pliant Therapeutics, Inc. (-5.58), greater than Black Diamond Therapeutics, Inc. (-3.31), greater than Arvinas, Inc. (-6.05),

Build a custom stock screener for RAPT Therapeutics, Inc. (RAPT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RAPT Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

RAPT Therapeutics, Inc. (RAPT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like RAPT Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is RAPT Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for RAPT Therapeutics, Inc. (RAPT)?

What is the highest PE Ratio for RAPT Therapeutics, Inc. (RAPT)?

What is the 3-year average PE Ratio for RAPT Therapeutics, Inc. (RAPT)?

What is the 5-year average PE Ratio for RAPT Therapeutics, Inc. (RAPT)?

How does the current PE Ratio for RAPT Therapeutics, Inc. (RAPT) compare to its historical average?